Back to Results
First PageMeta Content
Vascular endothelial growth factor / Ranibizumab / Health / Diabetic retinopathy / Macular edema / Genentech / Retina / Ophthalmology / Medicine / Angiology


FOR IMMEDIATE RELEASE Aerpio Therapeutics Initiates Phase 2 Study of Tie2 Activator AKB-9778 for the Treatment of Diabetic Macular Edema Cincinnati, OH, February 13, 2014 – Aerpio Therapeutics, Inc., a clinical-stage b
Add to Reading List

Document Date: 2014-02-13 16:12:56

Open Document

File Size: 284,97 KB

Share Result on Facebook

City

Cincinnati / Boston / /

Company

Genentech Inc. / Aerpio Therapeutics Inc. / /

/

Event

FDA Phase / Earnings Announcement / /

IndustryTerm

biopharmaceutical / clinical‐stage biopharmaceutical / therapies for vascular diseases / /

MedicalCondition

vascular diseases / persistent macular edema / disease / diabetic macular edema / /

MedicalTreatment

innovative therapies / Alternative therapies / /

Organization

American Academy of Ophthalmology / /

Person

Jeffrey Heier / Kevin Peters / Heather Behler / /

/

Position

Chief Scientific Officer and VP of Research and Development / Office Manager / leader in the development / /

Product

Lucentis / Tie2 / AKB-9778 / /

ProvinceOrState

Ohio / /

URL

www.aerpio.com / /

SocialTag